Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Angiodynamics Inc receives expanded FDA clearance for AngioVac


Tuesday, 11 Mar 2014 06:30am EDT 

Angiodynamics Inc:U.S. Food and Drug Administration (FDA) cleared expanded indication for AngioVac cannula for venous drainage during extracorporeal bypass for up to six hours to include removal of fresh, soft thrombi or emboli.AngioVac cannula and circuit, when combined with other manufacturers' filters, pumps and return cannula, comprise extracorporeal bypass circuit that facilitates drainage, filtration and reinfusion of blood for up to six hours. 

Company Quote

19.17
-0.02 -0.10%
26 Dec 2014